A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. - Wikidata - wikimedia - TriplyDB

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

http://www.wikidata.org/entity/Q33376773

about

Mechanisms of heparanase inhibitors in cancer therapy.Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management.Expression of heparanase in soft tissue sarcomas of adults.A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics.Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice.Structure and epitope distribution of heparan sulfate is disrupted in experimental lung hypoplasia: a glycobiological epigenetic cause for malformation?Synthetic, non-saccharide, glycosaminoglycan mimetics selectively target colon cancer stem cells.Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.Allele loss and down-regulation of heparanase gene are associated with the progression and poor prognosis of hepatocellular carcinoma.Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function Structural characterization of human heparanase reveals insights into substrate recognition.Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes.Microvessel density and heparanase over-expression in clear cell renal cell cancer: correlations and prognostic significances Heparanase is overexpressed in lung cancer and correlates inversely with patient survival Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling.Heparanase: busy at the cell surface.The prognostic significance of heparanase expression in metastatic melanoma Heparan sulfate in angiogenesis: a target for therapy.Down-regulation of heparanase leads to the inhibition of invasion and proliferation of A549 cells in vitro and in vivo.Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model.Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides--comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea.Heparin Mimetics: Their Therapeutic Potential.Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications.

P2860

Q30244089-DEA61797-2254-4E72-9895-0946D24A143B Q33350614-49AD3E8C-D440-4967-BFFA-C65124D7CDCA Q33634228-47BA9B1F-FD55-4A73-B50C-671652A93106 Q33752920-B1358FF7-4019-475C-90B1-98D3F95CD05F Q33879791-F32ED1B9-EB80-4F5E-BEF4-B01AD09AA813 Q33932177-AD5FDB08-E625-4360-A14F-2DC4F6E20E11 Q34061158-7EE99B27-8F4B-4F63-A95C-A6FFBED30256 Q34398151-4AADAB5A-6820-4B4B-B245-7FF147A21503 Q34406172-517D9329-D0D8-412D-8529-20B3915186E6 Q34426913-B73DE609-BA0B-41ED-BC24-D4F7949B9615 Q34501966-F55BD60C-19B4-4BD6-9BDF-5EEE07A9F0C3 Q34802543-30836BFB-27FD-4D0C-B8BA-2D180F851C22 Q35640553-BFB5DB4A-FE23-4050-A8D6-46DF18694922 Q35707564-67AA0401-8D39-4D7A-A0C9-1057DE7BE8E7 Q37059154-87A33D1F-CC16-44D4-B753-493019D9D13D Q37114794-D14F77B9-2E2D-4E02-B988-A7093C26C322 Q37116228-AA978A64-4D67-4338-99EC-FD7454931816 Q37371146-0A8E34F2-491A-4ADF-8BD5-A8EC84E83D75 Q37688833-8A66D5D4-A070-49F7-A46E-E14565EF4923 Q38154506-9F5790FC-B9DF-443B-9D5C-A1BF5F7C75B9 Q39225944-EBEBE593-2CF5-49A0-9ADE-F6F763F7FAF5 Q42224130-60C9BE06-99B4-4E6A-A0B0-A4515A4B0F1E Q43171467-1E987B6C-937E-4BEF-B969-DAF54BC15881 Q47159791-395C5DBB-1A7B-4AE2-9378-6B1E1B2DD363 Q48171089-91C037E1-474E-4F1B-9C6C-B0A1757A5A58

P2860

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

http://www.wikidata.org/entity/Q33376773

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

@ast

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

@en

type

label

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

@ast

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

@en

prefLabel

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

@ast

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

@en

P1433

Q33376773-52302744-91B9-4133-8065-E9CE3550780E

P1476

Q33376773-D4AC5E63-CC23-48BE-A600-D5890C401147

P2093

Q33376773-2D9EF62E-996D-4F4E-895F-728C942359AB

Q33376773-53232858-5ED0-493F-9104-68FFD46B53D9

Q33376773-98AAD5CA-6EEE-40FD-95A5-E6FF1B686649

Q33376773-99A082DA-A356-48EE-ACA9-AE81502FCAEF

Q33376773-A7DB9665-7283-4DE4-85C1-E9E7EE2E78B3

Q33376773-B9083E27-370A-4172-96F0-3D2F6E7157F2

Q33376773-BA255B10-1D77-4479-B6D3-3401A270A0F8

Q33376773-C55F6BA8-F2D9-473F-B110-60A8A5BA3DEC

Q33376773-EBDEA336-F6C5-4D7C-A28E-B341B903B1AF

Q33376773-EE283322-9673-4D07-A341-756B7417A151

P2888

Q33376773-C6CA5380-25B5-41A7-8182-76CE77A532E9

P304

Q33376773-12D3F16C-5384-481A-B360-2D4AF1DAF682

P31

Q33376773-30AEFC14-D27C-4C80-A54B-5545E9609E5D

P356

Q33376773-5E3A9827-9339-43C1-BD7C-2DAB2B5CB48E

P433

Q33376773-25CD6C7A-1F6F-42EA-9FFE-F822814C63E7

P478

Q33376773-C4FEC97C-6CA0-45DE-A668-CB8E920A6C32

P50

Q33376773-6E2F7DEB-6577-4971-BEB4-9CBCC4A16A24

Q33376773-86E799B6-7EC0-4334-874B-9C3070BC367F

P577

Q33376773-99A04F3D-422C-4651-A79E-69CDD48E9315

P6179

Q33376773-EE331800-EED8-4F3F-B326-B68CA708A9BF

P698

Q33376773-CA722F5F-AD1F-42B2-999C-3DA68165E1AC

P356

S10637-007-9080-5

P1433

Investigational New Drugs

P1476

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

@en

P2093

Alex Powell

http://www.w3.org/2001/XMLSchema#string

Andrew M Haydon

http://www.w3.org/2001/XMLSchema#string

Brian R Creese

http://www.w3.org/2001/XMLSchema#string

Damien B Thomson

http://www.w3.org/2001/XMLSchema#string

John R Zalcberg

http://www.w3.org/2001/XMLSchema#string

Karl D Lewis

http://www.w3.org/2001/XMLSchema#string

Kaye L Roberts

http://www.w3.org/2001/XMLSchema#string

Michael J Millward

http://www.w3.org/2001/XMLSchema#string

Rene Gonzalez

http://www.w3.org/2001/XMLSchema#string

William A Robinson

http://www.w3.org/2001/XMLSchema#string

P2888

s10637-007-9080-5

P304

89-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-007-9080-5

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1016118104

http://www.w3.org/2001/XMLSchema#string

P698

17891338

http://www.w3.org/2001/XMLSchema#string